Status:
TERMINATED
Effect of Serum LDL Cholesterol Concentration on Pancreatic Insulin Secretion
Lead Sponsor:
University Hospital Tuebingen
Conditions:
Hypercholesterolemia
Insulin Resistance
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Dyslipidemia is characterized by low levels of HDLs, hypertriglyceridemia as well as an increases proportion of small dense LDLs. Changes in lipoprotein particles and its concentrations, especially in...
Eligibility Criteria
Inclusion
- Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures
- Medical indication for the treatment with a PCSK9-inhibitor
- HbA1c \< 6,5%
Exclusion
- Diabetes mellitus
- Pregnant women or breastfeeding
- Hb \< 11.5 g/dl (males) or Hb \< 10.5 g/dl (females)
- treatment with any medication that effects on blood glucose concentrations, e.g. antidiabetic drugs or steroids
- Any pancreatic disease
Key Trial Info
Start Date :
July 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2024
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT04314167
Start Date
July 28 2020
End Date
March 1 2024
Last Update
May 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Tuebingen, Department of Internal Medicine IV
Tübingen, Germany, 72076